The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | MRD: decision making in CLL
MRD offers a huge advantage in the development of prognostics in chronic lymphocytic leukemia (CLL), but how does the technique impact decision making in the clinical environment? Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses this at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
